Panobinostat (LBH589): A novel pan-deacetylase inhibitor with activity in T cell lymphoma

Haematologica Meeting Reports

Volumn 3, Issue 1, 2009, Pages 33-38

  Prince, H M ^a   Bishton, M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; ROMIDEPSIN; STEROID; THALIDOMIDE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; FATIGUE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; QT INTERVAL; QT PROLONGATION; SIDE EFFECT; SOLID TUMOR; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 69749111046     PISSN: 19707339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999;94:417-428 (Pubitemid 29323855)
2. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-5432
3. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784 (Pubitemid 44348499)
4. Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Rev Anticancer Ther 2007;7:1439-1449 (Pubitemid 351826909)
5. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-3993 (Pubitemid 46218700)
6. Shao W, Growney JD, Feng Y, Wang P, Yan-Neale Y, O'Connor G, et al. Potent anticancer activity of the pandeacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models. 99th American Association Cancer Research Annual Meeting, 12-16 April, 2008, San Diego, California. Poster presentation. (Abstract 6244). 2008a
7. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006;66:5781-5789 (Pubitemid 43927132)
8. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441-3449 (Pubitemid 44776885)
9. Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Yao Y-M, et al. Efficacy of Panobinostat (LBH589) in CTCL Cell Lines and a Murine Xenograft Model: Defining Molecular Pathways of Panobinostat Activity in CTCL. ASH Annual Meeting Abstracts 2007;110:1375.
10. Growney JD, Atadja P, Shao W, Wang Y, Pu M, Firestone B, et al. Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma. ASH Annual Meeting Abstracts 2007;110:1510.
11. Atadja P, Shao W, Wang Y, Growney JD, Cheng J, Kowal C, et al. Potent anticancer activity of panobinostat (LBH589) in small-cell lung cancer in both in vitro and in vivo tumor models. Ann oncol 2008; viii50. Abstract 86.
12. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. Aphase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628-4635 (Pubitemid 44297814)
13. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol 2008;26:332-3; discussion 333-334
14. Sharma S, Vogelzang NJ, Beck J, Patnaik A, Mita M, Dugan M, et al. Phase I pharmacokinetic and pharmacodynamic study of once-weekly i.v. panobinostat (LBH589). European Cancer Conference (ECCO 14), 23-27 September 2007, Barcelona, Spain. Poster presentation.
15. Prince HM, George D, Patnaik A, Mita M, Dugan M, Butterfoss D, et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma. J Clin Oncol (Meeting Abstracts) 2007;25(18-suppl):3500.
16. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14:4500-4510
17. Duvic M, Becker JC, Dalle S, Vanaclocha F, Bernengo MG, Lebbe C, et al. Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL). ASH Annual Meeting Abstracts 2008;112:1005.
18. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007;13:2318-2322 (Pubitemid 46698579)
19. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25: 3109-3115 (Pubitemid 47218059)
20. Bates S, Piekarz R, Wright J, Frye R, Figg WD, Sr., Allen SL, et al. Final clinical results of a Phase 2 NCI multicenter study of romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included). ASH Annual Meeting Abstracts 2008;112:1568.
21. Ottmann OG, Spencer A, Prince HM, Bhalla KN, Fischer T, Liu A, et al. Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. ASH Annual Meeting Abstracts 2008;112:958.
22. Wolf JL, Siegel D, Matous J, Lonial S, Goldschmidt H, Schmitt S, et al. A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma. ASH Annual Meeting Abstracts 2008;112:2774.
23. Siegel Dd, Sezer O, San Miguel JF, Mateos M-V, Prosser I, Cavo M, et al. A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma. ASH Annual Meeting Abstracts 2008;112: 2781.